I wanted to research the state of peptides and longevity research in China by searching only Chinese language websites targeted at Chinese nationals in China. Claude is restricted to English only websites which I find fascinating. So, I asked Claude if Deep Seek could search Chinese language websites and the result was yes.
I down loaded the Deep Seek app and started talking.
As I hurt when I workout, even garden or play pickleball being able to recover quickly is a desirable thing. The “Wolverine stack” is a tempting peptide injection that is hyped to do this. I asked Deep Seek about it. The following is the summary of our conversation.
I post it here because it shows that there is a path to human trails, if a long scary and torturous one, that good lead to human trails for the peptides in the “Wolverine Stack” A path that does not exist at all in the USA.
I also want to point out Deep Seek as a way to peek into Chinese culture by directly reviewing the information pointed at the Chinese.
How is this related to MACRO economics. It is not directly related. It is related in a way. Almost half the population of the world is caught up in a population stack that no longer resembles a pyramid. Additionally these people represent most of the wealth in the world. As these people age, they have the same problem as me, they need to exercise for longevity, but that hurts. Peptides will be a large market one way or another. It would be helpful if there was actual human data on what works.
Also, for those interested in MACRO economics, looking inside what so believe is the largest economy in the world might be helpful.
DEEP SEEK SUMMARY
Here is a clear, organized summary of our entire conversation. You can share this directly with your friends or use it as a foundation for discussion.
Summary: Peptides, Patents, China, and the Wolverine Stack
The Core Problem (As You Identified It)
Peptides like BPC-157 and TB-500 show significant promise in animal studies for tissue regeneration, wound healing, and recovery. However, they lack rigorous human clinical trials. The reason is structural: these are naturally occurring peptides that cannot be patented as molecules. Without patent protection, no pharmaceutical company will invest the $100+ million required for human trials because any competitor could copy the drug immediately upon approval.
You described this as “crony capitalism” in the US system—a valid critique. The profit motive drives research, and when profit is impossible, research stalls.
The China Angle
You wondered whether China’s state-funded research model might offer a better way. China funds drug development based on strategic public health value, not just patent-driven profit. The infrastructure exists:
· Provincial grants of $1.4M–$2.8M for peptide drug development
· State-linked investment funds specifically targeting peptide therapeutics
· A growing peptide CRDMO (Contract Research, Development, and Manufacturing Organization) industry
However, the reality check is that Chinese institutions have not yet applied for grants to study BPC-157 or TB-500 specifically. These peptides remain in a research-use-only gray zone in China, similar to the US.
Personal Access: US vs. China
You asked whether moving to China would make it easier to obtain these peptides for personal use.
The answer is no. In fact, it is currently easier and safer for an individual to source these peptides in the US than in China. Chinese enforcement on unapproved substances can be severe, and the peptides are sold only “for research use” to institutions, not individuals.
The Wolverine Stack Patent Strategy
You proposed a clever workaround: instead of patenting the individual peptides (which is impossible), patent the combination—the “Wolverine Stack” (BPC-157 + TB-500 in a specific ratio or formulation).
Under Chinese patent law, this is possible if you can demonstrate synergy: that the combination works better than either peptide alone.
You then proposed using the patent not to exclude others, but as a funding tool—to attract investment or grants to conduct the three necessary studies:
- BPC-157 alone (human data)
- TB-500 alone (human data)
- The Wolverine Stack (to prove synergy)
And then, after the research is done, dedicate the patent to the public domain so anyone can use it.
The BPC-HAMSTR Trial
A Phase 2 clinical trial of BPC-157 for acute hamstring injuries is actively recruiting as of February 2026.
· Sponsor: Hudson Biotech
· Primary completion date: Estimated February 14, 2027
· Study completion date: Estimated February 17, 2028
This is the first serious human trial for BPC-157 and is worth watching.
The Pitching Model: You Stay in the US
You asked whether you could pitch the patent idea to a Chinese company without moving to China, without investing your own money, and without doing the work yourself.
Yes. This is possible under existing business models.
Model How It Works Your Role
Traditional Licensing Chinese company licenses your patent, funds all development, pays you royalties Passive income (upfront + milestones + royalties)
NewCo Model A new company is formed with your patent. You receive equity. The company is later sold. Passive equity holder
Royalty reality: Under CNIPA guidelines, royalty rates typically range up to 20% of net sales or 40% of profit.
Precedent: In 2025, Innovent Biologics (China) paid Takeda (Japan) $1.2 billion upfront for a co-development deal. Chinese companies will pay for innovative IP.
The Practical Steps (If You Wanted to Pursue This)
- File a Chinese patent (via a licensed Chinese agent). Cost: $2,000–$5,000 USD.
- Target a Chinese peptide CRDMO like Tide Pharmaceutical or Medtide.
- Pitch the licensed opportunity using an NDA-protected template.
- Remain in the US throughout. No relocation required.
The Current State of Human Data (Summary)
Peptide Human Studies Quality of Evidence
BPC-157 1 pilot study (n=12, interstitial cystitis); 1 ongoing Phase 2 trial Low; Phase 2 results pending 2027–2028
TB-500 Case reports only Very low
MOTS-c Observational studies only (measuring natural levels) No interventional data
Wolverine Stack None No human data on combination
The Bottom Line
Your diagnosis of the problem is correct: the patent system fails naturally occurring peptides, and as a result, human data is dangerously lacking.
China’s state-funded model could solve this in theory, but hasn’t yet for these specific peptides.
The patent strategy for the Wolverine Stack is legally viable under Chinese law, and you could theoretically pitch it to a Chinese company while remaining a “big fat American” at home.
The biggest missing piece remains human data—and the BPC-HAMSTR trial results in 2027–2028 will be the first real signal of whether BPC-157 works in humans at all.
Feel free to share this with your friends. If they have questions or want to push further into any of these areas, I’m happy to help.
Cheers
Qazulight
The Wolverine Stack Expained